Prathyusha Duraibabu Sangamo Therapeutics, Inc (SGMO) insider trading activity

Prathyusha Duraibabu is SVP, CHIEF FINANCIAL OFFICER of SANGAMO THERAPEUTICS, INC. Currently has a direct ownership of 830,528 shares of SGMO, which is worth approximately $373,737. The most recent transaction as insider was on Jun 11, 2024, when has been sold 892 shares (Common Stock) at a price of $0.61 per share, resulting in proceeds of $544. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 831K

0.49% 3M change

521.36% 12M change

Total Value Held $373,737

Prathyusha Duraibabu Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 11 2024	SELL Payment of exercise price or tax liability	$544 $0.61 p/Share	892 Reduced 0.11%	830,528 Common Stock
May 25 2024	SELL Payment of exercise price or tax liability	$822 $0.6 p/Share	1,371 Reduced 0.16%	831,420 Common Stock
May 24 2024	SELL Payment of exercise price or tax liability	$1,072 $0.6 p/Share	1,787 Reduced 0.21%	832,791 Common Stock
Feb 25 2024	SELL Payment of exercise price or tax liability	$3,901 $1.13 p/Share	3,453 Reduced 0.41%	834,578 Common Stock
Feb 24 2024	SELL Payment of exercise price or tax liability	$6,185 $1.13 p/Share	5,474 Reduced 0.65%	838,031 Common Stock
Jan 22 2024	BUY Grant, award, or other acquisition	-	712,500 Added 45.79%	843,505 Common Stock
Nov 25 2023	SELL Payment of exercise price or tax liability	$505 $0.38 p/Share	1,329 Reduced 1.0%	131,005 Common Stock

Aug 25 2023	SELL Payment of exercise price or tax liability	$1,023 $0.77 p/Share	1,329 Reduced 0.99%	132,334 Common Stock
Jun 11 2023	SELL Payment of exercise price or tax liability	$1,028 $1.19 p/Share	864 Reduced 0.64%	133,663 Common Stock
May 25 2023	SELL Payment of exercise price or tax liability	$1,766 $1.33 p/Share	1,328 Reduced 1.0%	132,052 Common Stock
Mar 25 2023	SELL Payment of exercise price or tax liability	$572 $1.66 p/Share	345 Reduced 0.26%	133,380 Common Stock
Feb 25 2023	SELL Payment of exercise price or tax liability	$18,699 $2.66 p/Share	7,030 Reduced 4.99%	133,725 Common Stock
Feb 24 2023	BUY Grant, award, or other acquisition	-	53,438 Added 27.52%	140,755 Common Stock
Jun 11 2022	SELL Payment of exercise price or tax liability	$3,166 $3.76 p/Share	842 Reduced 0.96%	86,617 Common Stock
Apr 25 2022	SELL Payment of exercise price or tax liability	$3,197 $4.83 p/Share	662 Reduced 0.76%	86,772 Common Stock
Mar 25 2022	SELL Payment of exercise price or tax liability	$1,984 $5.75 p/Share	345 Reduced 0.39%	87,434 Common Stock
Feb 25 2022	SELL Payment of exercise price or tax liability	$20,497 $5.9 p/Share	3,474 Reduced 6.91%	46,779 Common Stock
Feb 25 2022	BUY Grant, award, or other acquisition	-	41,000 Added 31.84%	87,779 Common Stock
Jun 11 2021	BUY Grant, award, or other acquisition	-	7,500 Added 13.08%	49,827 Common Stock
Apr 25 2021	SELL Payment of exercise price or tax liability	$7,752 $11.71 p/Share	662 Reduced 1.62%	40,128 Common Stock
Mar 25 2021	SELL Payment of exercise price or tax liability	$4,233 $12.27 p/Share	345 Reduced 0.84%	40,790 Common Stock
Feb 25 2021	SELL Payment of exercise price or tax liability	$20,847 $11.19 p/Share	1,863 Reduced 6.37%	27,385 Common Stock
Feb 25 2021	BUY Grant, award, or other acquisition	-	13,750 Added 25.05%	41,135 Common Stock

Also insider at

ORGO

Organogenesis Holdings Inc. Healthcare

Director